Could a simple immune boost stop recurrent miscarriages?
NCT ID NCT03970954
First seen Nov 01, 2025 · Last updated Jun 18, 2026 · Updated 37 times
Summary
This early-phase study tested whether low doses of a protein called interleukin-2 (IL-2) could increase regulatory T cells—immune cells that help the body accept a pregnancy—in 18 women who had at least five unexplained early miscarriages. The goal was to see if this approach could prevent the immune system from rejecting the fetus. The study measured changes in blood Treg levels but did not directly assess pregnancy outcomes, so more research is needed to know if it truly reduces miscarriage risk.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT MISCARRIAGE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Bornes
Paris, Hopital Tenon, 75020, France
-
Kayem
Paris, Hopital Trousseau, 75012, France
-
Mekinian
Paris, Hopital Saint Antoine, 75012, France
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.